πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 106 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10907175

Isolated human cell with an inactivated glucocorticoid receptor gene

Sangamo Therapeutics, Inc. Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10888589

Modulation of stem cells using zinc finger proteins

Sangamo Therapeutics, Inc. Β· Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10889834

Methods and compositions for enhancing targeted transgene integration

Sangamo Therapeutics, Inc. Β· Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10883119

Methods and compositions for delivery of biologics

Sangamo Therapeutics, Inc. Β· Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10857203

Methods and compositions for treating Huntington's disease

Sangamo Therapeutics, Inc. Β· Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10828376

Liver-specific constructs and methods of use thereof

Sangamo Therapeutics, Inc. Β· Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10822599

Compositions for linking DNA-binding domains and cleavage domains

Sangamo Therapeutics, Inc. Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10808020

Nuclease-mediated regulation of gene expression

Sangamo Therapeutics, Inc. Β· Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10724020

Compositions for linking DNA-binding domains and cleavage domains

Sangamo Therapeutics, Inc. Β· Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10717993

Methods and compositions for increased transgene expression

Sangamo Therapeutics, Inc. Β· Granted Tue Jul 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10689717

Methods and compositions for targeted single-stranded cleavage and targeted integration

Sangamo Therapeutics, Inc. Β· Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10675302

Methods and compositions for targeted cleavage and recombination

Sangamo Therapeutics, Inc. Β· Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10646543

Methods and compositions for treating trinucleotide repeat disorders

Sangamo Therapeutics, Inc. Β· Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10648001

Method of treating mucopolysaccharidosis type I or II

Sangamo Therapeutics, Inc. Β· Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10639383

Methods and compositions for engineering immunity

Sangamo Therapeutics, Inc. Β· Granted Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10619154

Nuclease-mediated regulation of gene expression

Sangamo Therapeutics, Inc. Β· Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10604771

Delivery methods and compositions for nuclease-mediated genome engineering

Sangamo Therapeutics, Inc. Β· Granted Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10563184

Regulation of gene expression using engineered nucleases

Sangamo Therapeutics, Inc. Β· Granted Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10538787

Compositions for linking DNA-binding domains and cleavage domains

Sangamo Therapeutics, Inc. Β· Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10500229

Targeted disruption of the MHC cell receptor

Sangamo Therapeutics, Inc. Β· Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10494648

Delivery methods and compositions for nuclease-mediated genome engineering

Sangamo Therapeutics, Inc. Β· Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10471123

Methods and compositions for treating Huntington's disease

Sangamo Therapeutics, Inc. Β· Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10450585

Delivery methods and compositions for nuclease-mediated genome engineering

Sangamo Therapeutics, Inc. Β· Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10435441

HTT repressors and uses thereof

Sangamo Therapeutics, Inc. Β· Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted